Marc Appel, JD, MBA, currently serves as an advisor to numerous university innovation programs, including the Blavatnik program at Yale University, the tech transfer office at Cornell University, and the Dartmouth Innovations Accelerator for Cancer. Previously, he founded Orange Grove Bio, a drug investment and development firm and served as the organization's first CEO from 2019 through early 2024. He additionally has led the founding teams of numerous biotech companies including IpiNovyx Bio and Allonix Therapeutics. 

As an experienced investor in the healthcare and biotech spaces, he helped to build the structured healthcare and royalty investing strategy at Marathon Asset Management, where he was instrumental on a range of large biotech deals. Prior to that, he invested across the capital structure in public market healthcare opportunities in the specialty pharma, hospital, outpatient services, drug distribution, and biotech sectors. 

Previously, Marc held roles at Highbridge Principal Strategies, Eaton Vance, and Kirkland & Ellis. He began his career as an analyst at McKinsey & Co., serving a mix of financial services and healthcare clients.Marc speaks on many industry panels and conferences, including those hosted by universities, BIO, RESI, CBI, SAPA, InformaConnect, and PBMI. He has authored a Harvard Business School case study on Imprimis Pharmaceuticals and has lectured at Harvard Business School, Harvard Law School, Yale School of Management, University of Cincinnati Law School, and Stern School of Business at New York University.

Marc received his B.A. from Yale University, summa cum laude, his J.D. from Harvard Law School, and his M.B.A. from Harvard Business School. He is an active member of the New York Bar.